Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Market Closed 07-24 16:00:00 EDT

0.6320

+0.0010

+0.16%

盘后0.6120

-0.0200-3.16%

17:32 EDT

High0.6996	Low0.6130	Vol18.23K
Open0.6990	D1 Closing0.6310	Amplitude13.72%
Mkt Cap7.83M	Tradable Cap4.68M	Total Shares12.38M
T/O11.97K	T/O Rate0.25%	Tradable Shares7.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.632,"timestamp":1784923200000,"preClose":0.631,"halted":0,"volume":18228,"hourTrading":{"tag":"盘后","latestPrice":0.612,"preClose":0.632,"latestTime":"17:32 EDT","volume":3107,"amount":1933.2708,"timestamp":1784928757368,"change":-0.02,"changeRate":-0.031646,"amplitude":0.031646},"delay":0,"changeRate":0.0015847860538827272,"floatShares":7410700,"shares":12382776,"eps":-1.49,"marketStatus":"Market Closed","change":0.001,"latestTime":"07-24 16:00:00 EDT","open":0.699,"high":0.6996,"low":0.613,"amount":11972.44861008,"amplitude":0.137242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.49,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.631,"postHourTrading":{"tag":"盘后","latestPrice":0.612,"preClose":0.632,"latestTime":"17:32 EDT","volume":3107,"amount":1933.2708,"timestamp":1784928757368,"change":-0.02,"changeRate":-0.031646,"amplitude":0.031646},"volumeRatio":0.4666676847905233,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE/wiki","defaultTab":"wiki","newsList":[{"id":"2653775446","title":"Aprea Therapeutics Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653775446?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:27","pubTimestamp":1784838452,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics gets Nasdaq extension to regain $1 minimum bid price complianceAprea Therapeutics received a Nasdaq notice granting a second 180-day window to regain $1 minimum bid-price compliance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL2rxdRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644072977","title":"Aprea Therapeutics shareholders elect three Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644072977","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644072977?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:16","pubTimestamp":1781727385,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics held its annual shareholder meeting on June 16, 2026.Investors approved a charter amendment authorizing the board to carry out a reverse stock split.If implemented, the reverse split ratio can range from 1-for-3 to 1-for-8, with any fractional shares rounded up.Shareholders ratified EisnerAmper as the independent registered public accounting firm for the 2026 fiscal year.Shareholders selected a non-binding advisory vote to hold future say-on-pay votes every year.An adjournment proposal was adopted to allow more time to solicit votes if needed to secure support for the reverse stock split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLSP81m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640088959","title":"Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640088959","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640088959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:06","pubTimestamp":1780315579,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics presented updated Phase 1 results for WEE1 inhibitor APR-1051 at ASCO 2026 on May 30.Early data showed signs of tumor shrinkage in some endometrial cancer patients, with disease control in additional heavily pretreated solid tumors.Side effects were described as manageable, supporting continued dose escalation and a path toward selecting a later-stage dose.The trial is expanding enrollment into uterine serous carcinoma, with a separate expansion in platinum-resistant ovarian cancer.Dose escalation and backfill expansion are expected to complete in Q2 2027, setting up potential Phase 2 planning.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4yct9f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","APRE","IE00BGHQF748.EUR","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014013.SGD","SG9999014005.SGD","BK4585","BK4139","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030211","title":"Aprea Therapeutics - Files for Resale of up to 5.5 Mln Shares by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030211?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:39","pubTimestamp":1778877569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nFWN41S1FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635807577","title":"Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635807577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635807577?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:31","pubTimestamp":1778679111,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAprea Therapeutics Inc APRE.OQ reported a quarterly adjusted loss of 22 cents per share for the quarter ended Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635783232","title":"Aprea Therapeutics Q1 net loss narrows as R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635783232","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635783232?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:37","pubTimestamp":1778668621,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Q1 net loss narrows as R&D expenses fallOverviewUS precision oncology firm's Q1 net loss narrowed yr/yr as R&D expenses declinedCash and cash equivalents rose to $46.5 mln after $30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635783660","title":"Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635783660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635783660?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:30","pubTimestamp":1778668200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA6TMRQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635783668","title":"Aprea Therapeutics Q1 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2635783668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635783668?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:30","pubTimestamp":1778668200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX4BD5BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635553228","title":"Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2635553228","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635553228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:39","pubTimestamp":1778618340,"startTime":"0","endTime":"0","summary":"COMMODITIES: Oil futures rose as the Strait of Hormuz remained shut due to a stalemate between the U.S. and Iran.Inflation Soared to 3.8% in April, Driven by Gasoline Prices. Consumer prices rose 3.8% in April from a year earlier, a clear impact of higher gas prices since the start of the war with Iran.The figures, reported Tuesday by the Labor Department, surpassed the previous month's reported increase of 3.3%. Economists polled by The Wall Street Journal had expected inflation of 3.7%. The April increase was the highest in three years.Kevin Warsh Confirmed as Fed Gov, Chair Vote Expected This Week. Trump Can Keep Collecting Global 10% Tariffs After Appeals Court Stays Decision. The appeals court agreed to stay last week's trade court decision and granted the administration a temporary but immediate stay \"until further notice\" while it considers the administration's appeal of that ruling.Jack Daniel's maker Brown-Forman rejected a roughly $15 billion takeover offer from rival Sazerac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBC","XLE","UCO","ABUS","DUG","ABEO","BNO","BK4547","AIM","XOP","USE","DBO","XES","IEO","IXC","UGA","WTIU","APRE","PXE","DBE","BK4167","PXJ","GME","DIG","BBGI","CLNN","BWET","GUSH","OILK","FTXN","VDE","DRIP","BK4570","BK4125","USL","USO","ALT","ERX","IGME","OIH","OILU","SCO","CABA","USOI","DRLL","GMEU","BK4139","GMEY","OILT","DRIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635228328","title":"Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins","url":"https://stock-news.laohu8.com/highlight/detail?id=2635228328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635228328?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:34","pubTimestamp":1778618040,"startTime":"0","endTime":"0","summary":"Pet Valu Trims Earnings Forecast as Value-Seeking Consumers Squeeze Margins. Pet Valu's customers aren't shaking their bargain-hunting trend, as value-seeking behavior tightens its grip on how Canadians buy pet products.\"We saw higher discount sales penetration as heightened value-seeking industrywide saw devoted pet lovers lean heavier into periods of events and promotions, which weighed on our margin rate in the quarter,\" said Chief Executive Greg Ramier in an earnings call.Keyera Finalizes Buy of Plains' Canadian Assets Even as Regulatory Threat Looms. Keyera has finalized the roughly $3.9 billion acquisition of Plains All American Pipeline's natural gas liquids business in Canada despite the threat of regulatory opposition.The transaction closed in its entirety, Keyera said, wrapping up the Canadian energy company's largest-ever takeover.The assets were picked up for C$5.3 billion, including closing adjustments. The deal was funded in part by a C$2.07 billion sale of subscription r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USE","PXE","ABUS","LU1878469433.USD","VDE","BK4599","BK4588","BK4557","DRLL","XES","DIG","IXC","ERX","AIM","DUG","ALT","WTIU","PXJ","FTXN","XOP","ABEO","DBE","DBC","IEO","GUSH","BK4139","BK4585","DRIP","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633686654","title":"Aprea Therapeutics Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633686654","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633686654?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:37","pubTimestamp":1778254639,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc  expected to post a loss of23cents a share - Earnings Preview Aprea Therapeutics Inc APRE.OQ APRE.O is expected to  report resultson May 12 (estimated) for the period ending Mar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633425191","title":"Aprea Therapeutics, Inc. :  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2633425191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633425191?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:20","pubTimestamp":1778156437,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nAZN4SUVBH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4120","LU2125910336.SGD","CLH","LU2125909916.SGD","LU0106261612.USD","LU2041044095.USD","LU0012050646.USD","LU1923622291.USD","LU2360108059.USD","SG9999014021.USD","LU1923621640.USD","LU1892829315.USD","LU2125910179.SGD","BK4139","SG9999014013.SGD","LU1880398554.USD","LU0757428866.USD","LU1923622614.USD","SGXZ99366536.SGD","APRE","LU2298321311.HKD","LU2125909759.SGD","SGXZ81514606.USD","SGXZ51526630.SGD","LU1880398471.USD","LU2125909593.SGD","LU0963586101.USD","LU1815336091.USD","LU2308191902.HKD","LU2092937221.SGD","LU2433249047.HKD","LU2125909247.SGD","SG9999014005.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629075375","title":"Aprea Therapeutics files to sell 74.35M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2629075375","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629075375?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:06","pubTimestamp":1776891993,"startTime":"0","endTime":"0","summary":"17:02 EDT Aprea Therapeutics (APRE) files to sell 74.35M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-74-35m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-files-to-sell-74-35m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APRE","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629030553","title":"Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629030553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629030553?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:15","pubTimestamp":1776780917,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics set a clinical update for ACESOT-1051, a first-in-human Phase 1 trial of WEE1 inhibitor APR-1051 in advanced solid tumors, at ASCO 2026.Initial trial results will be presented in a poster session on May 30, 2026, during ASCO Annual Meeting in Chicago.Disclosure signals early readout from APR-1051 development program, a key catalyst for assessing clinical viability in biomarker-defined oncology.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL1g1sjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","BK4139","NDAQ","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","BK4112","APRE","IE00BGHQF748.EUR","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629803082","title":"Aprea Therapeutics to Provide Clinical Update on Acesot-1051 Phase 1 Trial Evaluating Wee1 Inhibitor, Apr-1051, at Asco 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629803082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629803082?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:15","pubTimestamp":1776780900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA1CN5D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628744833","title":"Aprea Therapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628744833","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628744833?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:31","pubTimestamp":1776681087,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics will hold its 2026 annual meeting of stockholders virtually on June 16, 2026.Shareholders will vote on election of three Class I directors to three-year terms expiring in 2029.Ballot includes ratification of EisnerAmper as independent registered public accounting firm for fiscal 2026.Investors will consider an amendment to authorize a reverse stock split at a ratio between 1-for-3 and 1-for-8.Agenda also includes advisory votes on executive compensation, say-on-pay frequency, and potential adjournment to solicit additional proxies for reverse split proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL2sDl1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625956288","title":"Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625956288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625956288?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:55","pubTimestamp":1775570118,"startTime":"0","endTime":"0","summary":"In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics, with a price target of $5.00. McCarthy c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515660","title":"Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515660","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515660?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046624,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics closed an oversubscribed private placement with gross proceeds of about $30 million.Financing included pre-funded warrants covering about 37.2 million shares.Deal also included warrants covering about 37.2 million shares with an exercise price of $0.683 per share.Net proceeds will fund general corporate purposes, including R&D to advance APR-1051 clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbHgCT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","BK4139","SG9999014005.SGD","IE00BN0W2W23.USD","LU2095319765.USD","LU2210149790.SGD","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515536","title":"Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515536?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA8NY6RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300610","title":"Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623300610?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:10","pubTimestamp":1774951816,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nAZN4SO9G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":-0.1092},{"period":"1month","weight":-0.2181},{"period":"3month","weight":-0.3204},{"period":"6month","weight":-0.2386},{"period":"1year","weight":-0.6725},{"period":"ytd","weight":-0.2591}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.117728},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.094212},{"month":6,"riseRate":0.285714,"avgChangeRate":0.005319},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.06838},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction